MedPath

Role of Escitalopram Add-on in schizophrenia having subsyndromal depressive symptoms

Phase 4
Completed
Conditions
Health Condition 1: null- STABLE SCHIZOPHRENIA
Registration Number
CTRI/2018/01/011551
Lead Sponsor
Pooja Singh
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
66
Inclusion Criteria

1)Patients aged between 18 to 50 years.

2)Availability of a reliable informant.

3)Written informed consent from the patient and/or informant.

4)Diagnosis of Schizophrenia as per ICD-10, DCR.

5)Satisfying operational definition of stable schizophrenia.

6)Having SSDs as defined for the purpose of this study

Exclusion Criteria

1)Patients having clinically significant medical disorder / disability or taking treatment for same.

2)Any comorbid psychiatric disorder other than nicotine dependence.

3)Patients already receiving antidepressants or mood stabilisers during last 8 weeks.

4)Patients who have received electroconvulsive therapy, other somatic treatments or any form of Psychotherapy during the last six months.

5)Any significant abnormality in routine investigations at baseline (Hb, TLC, DLC, RBS, S.Urea, S.Creatinine, LFT)

6)Pregnant and lactating females.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
PANSS, HAM-D, SOFAS, SCoRSTimepoint: at 8 weeks
Secondary Outcome Measures
NameTimeMethod
PANSS, SOFAS, HAM-D, SCoRSTimepoint: 4 WEEKS
© Copyright 2025. All Rights Reserved by MedPath